Product image of Kardatuxan (Rivaroxaban) supplied by GNH India

Kardatuxan

Active Ingredient:
Rivaroxaban
Origin:
EU

Kardatuxan (Rivaroxaban)

Rivaroxaban, the active ingredient in Kardatuxan, is a direct factor Xa inhibitor presented as an oral tablet for oral use. It is indicated for prevention of stroke and systemic embolism in non‑valvular atrial fibrillation and for treatment and secondary prevention of deep‑vein thrombosis and pulmonary embolism, including postoperative thromboprophylaxis after hip or knee replacement.
GNH India supplies Kardatuxan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Gedeon Richter România S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Kardatuxan, a direct factor Xa inhibitor, is employed in several thrombo‑embolic conditions.

  • Non‑valvular atrial fibrillation: reduces risk of stroke and systemic embolism.
  • Deep vein thrombosis and pulmonary embolism: treats acute events and prevents recurrence.
  • Post‑operative thromboprophylaxis: lowers incidence of clot formation after hip or knee replacement surgery.

How It Works

  • Rivaroxaban selectively and directly inhibits factor Xa in the coagulation cascade, blocking the conversion of prothrombin to thrombin. By reducing thrombin generation, it diminishes fibrin clot formation without requiring antithrombin as a cofactor, providing anticoagulation across the intrinsic and extrinsic pathways.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

  • Bleeding (including gastrointestinal and mucosal).
  • Bruising or hematoma formation.
  • Nausea or dyspepsia.
  • Diarrhea.
  • Headache.
  • Dizziness.

Serious or Rare Side Effects

  • Intracranial hemorrhage.
  • Spinal or epidural hematoma, especially after neuraxial procedures.
  • Severe allergic reactions (anaphylaxis, angioedema).
  • Elevated liver enzymes or hepatic injury.
  • Myocardial infarction or acute coronary syndrome.

Precautions & Warnings

Before initiating therapy, consider patient‑specific risk factors and monitor appropriately.

  • Renal impairment: adjust use based on creatinine clearance.
  • Hepatic disease: avoid in patients with significant liver dysfunction.
  • Concomitant antiplatelet or NSAID therapy: increase bleeding risk.
  • Upcoming surgery or invasive procedures: discontinue according to clinical guidelines.
  • Pregnancy and breastfeeding: generally contraindicated due to limited safety data.
  • Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Rivaroxaban may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Other anticoagulants (e.g., warfarin, heparin).
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole).
  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine).
  • Potent P‑glycoprotein inhibitors (e.g., verapamil).
  • Antiplatelet agents (e.g., clopidogrel, aspirin).

Moderate Interactions (Monitor Closely)

  • Moderate CYP3A4 inhibitors (e.g., erythromycin).
  • Moderate P‑glycoprotein inhibitors (e.g., amiodarone).
  • Selective serotonin reuptake inhibitors (SSRIs).
  • Diuretics that may affect renal function.
  • Herbal products such as St. John’s wort.

Frequently Asked Questions

Kardatuxan contains rivaroxaban, an oral anticoagulant prescribed to lower the risk of stroke in patients with non‑valvular atrial fibrillation and to treat or prevent recurrence of deep‑vein thrombosis and pulmonary embolism, including after hip or knee replacement surgery.

Rivaroxaban works by selectively inhibiting factor Xa, a key enzyme in the coagulation cascade. This blocks the conversion of prothrombin to thrombin, reducing fibrin clot formation and providing anticoagulation without the need for antithrombin as a cofactor.

The dose of Kardatuxan is individualized by the prescribing clinician based on the specific indication, renal function, and patient characteristics. Healthcare professionals determine the appropriate strength and dosing schedule for each patient.

Safety data for rivaroxaban during pregnancy and lactation are limited. Because of potential risks to the fetus or infant, Kardatuxan is generally avoided in pregnant or breastfeeding women unless the benefits clearly outweigh the risks and are assessed by a qualified physician.

To request Kardatuxan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to rivaroxaban is warfarin, a vitamin K antagonist. Unlike warfarin, rivaroxaban has a predictable anticoagulant effect, does not require routine INR monitoring, and has fewer food and drug interactions, though both carry bleeding risk and have specific contraindications.

Kardatuxan tablets should be stored at temperatures below 25 °C in their original packaging, protected from moisture and direct sunlight. Keep the container tightly closed and out of reach of children to maintain product integrity.

Kardatuxan is taken orally, usually with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically advised.

The most serious risks include severe or uncontrolled bleeding, such as intracranial hemorrhage or spinal/epidural hematoma, especially after invasive procedures. Patients should also be alert for signs of allergic reactions, liver injury, and rare cardiovascular events.

Kardatuxan is contraindicated in individuals with active pathological bleeding, severe hepatic impairment, or a known hypersensitivity to rivaroxaban or any tablet components. It should also be avoided in patients who are pregnant or breastfeeding unless a specialist determines the benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Rivaroxaban

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT